Stentys SA (EPA:STNT) is looking to prove its next-generation Apposition IV stent in a head-to-head study against Medtronic’s (NYSE:MDT) Resolute.
Stentys calls its suite of Apposition stents the "world’s 1st and only self-apposing stent to treat acute myocardial infarction," with a shape and size that adapts to "fit snugly" into blood vessels to prevent gaps that can lead to blood clots.
"Long-term malapposition of drug-eluting stents has been associated with late stent thrombosis, so this randomized trial with the new Stentys sirolimus-eluting self-apposing stent will be carefully followed by the community," co-principal investigator Dr. William Wijns said in prepared remarks. Wijns is also chairman of the European Assn. of Percutaneous Cardiovascular Interventions.
The Princeton, N.J.-based company will enroll 150 heart attack patients into a randomized, multi-center study will follow-up at 4 and 9 months.
Stentys expects to complete trial enrollment before the end of the year, with results available by the 2nd half of 2013 and CE Mark approval in the European Union in the 2nd half of 2014, according to a press release.
More medical device research & development news:
- MIT researchers develop a fuel cell powered by the glucose in the human brain
- Laparoscopic gastric bypass safer than open surgery, study finds
- W.L. Gore launches quality improvement study for hernia repair mesh
- CardioFocus touts HeartLight study finding 98% acute success in pulmonary isolation with single ablation procedure
- Endosense closes enrollment in TactiCath force-sensing ablation catheter study
- Svelte Medical launches Faaster post-market registry for its Svelte coronary stent
- SalutarisMD presents latest data on Wet Age-related Macular Degeneration treatment with episcleral brachytherapy
- Researchers associate erectile dysfunction with sleep apnea sufferers under the age of 60
- CardiAQ touts 1st-in-human non-surgical percutaneous bioprosthetic mitral heart valve implant
- ReCor Medical reports 6-month hypertension reduction with its Paradise ultrasound-based renal denervation system
- Toshiba notes radiation dose reduction with AIDR 3D CT scanner
- Titan Medical makes progress with its robotic single-site surgical platform in user study
- Patients whose arteries re-close after stenting more than twice as likely to die within 7 years, UCLA researchers find
- Lombard’s Aorfix endovascular stent works well in patients with complex neck anatomy
